Barium: rationale for a new oral reference dose

The U.S. Environmental Protection Agency (EPA) has an established oral reference dose (RfD) value for Ba of 0.07 mg Ba/kg/d based on a 1984 investigation that reported hypertension. In this study, the toxicological data for Ba has been reevaluated and a revised oral RfD is proposed. The toxicokinetic, acute, and chronic toxicity, carcinogenicity, and reproductive animal studies as well as epidemiological and occupational health human studies for Ba exposure were reviewed for applicability to an oral RfD. The available human studies have some utility but suffer from either a small population size, a short exposure regimen, or difficulties in identifying definitive Ba exposure in the study population. As a result, the available long-term animal studies were found to be more appropriate for the RfD derivation. A dose-response assessment of no-observed-adverse-effect level (NOAEL) and lowest-observed-adverse-effect level (LOAEL) values determined that kidney effects are the most sensitive endpoint for adverse health effects related to chronic soluble Ba ingestion in mammals. The most complete animal studies were conducted by the National Toxicology Program (NTP, 1994) and the lowest species NOAELs were 75 mg Ba/kg/d in male mice and 60 mg Ba/kg/d for male rats. The male rats were identified to be the most sensitive population tested and their NOAEL value was selected for extrapolation to an oral RfD. Application of overall uncertainty factors to the lowest NOAEL value from a chronic animal study of either 90 (based on an approach proposed by Dourson, 1994) or the generally accepted 100 results in an oral RfD of 0.66 mg Ba/kg/d or 0.6 mg Ba/kg/d, respectively. It is proposed to use the more conservative value of 0.6 mg Ba/kg/d. This reassessment results in nearly an order of magnitude increase in the U.S. EPA oral RfD for Ba.